Publications by authors named "S T Esparza"
Article Synopsis
- Chemotherapy, particularly platinums, has been found to promote changes in lymphatic systems that could unintentionally enhance cancer malignancy instead of just inhibiting tumor growth.
- In experiments with mouse models and human patients, platinums induced systemic lymphangiogenesis, which is the formation of new lymphatic vessels, and this effect was shown to be dose-dependent and long-lasting.
- The study suggests that blocking these lymphatic changes with VEGFR3 inhibitors could improve treatment outcomes, advocating for adjustments in cancer therapies that involve platinum-based drugs.
Particle agglutination assays are widely adopted immunological tests that are based on antigen-antibody interactions. Antibody-coated microscopic particles are mixed with a test sample that potentially contains the target antigen, as a result of which the particles form clusters, with a size that is a function of the antigen concentration and the reaction time. Here, we present a quantitative particle agglutination assay that combines mobile lens-free microscopy and deep learning for rapidly measuring the concentration of a target analyte; as its proof-of-concept, we demonstrate high-sensitivity C-reactive protein (hs-CRP) testing using human serum samples.
View Article and Find Full Text PDFThe ASXL1 and SRSF2 mutations in AML are frequently found in patients with preexisting myeloid malignancies and are individually associated with poor outcomes. In this multi-institutional retrospective analysis, we assessed the genetic features and clinical outcomes of 43 patients with ASXL1 SRSF2 AML and compared outcomes to patients with either ASXL1 (n = 57) or SRSF2 (n = 70) mutations. Twenty-six (60%) had secondary-AML (s-AML).
View Article and Find Full Text PDFContext: Musculoskeletal injury is the leading cause of attrition from military training.
Objective: To assess the effect of an embedded athletic training musculoskeletal care model within a basic military training unit.
Design: Cluster randomized trial.
The measurement of serum phosphate concentration is crucial for patients with advanced chronic kidney disease (CKD) and those on maintenance dialysis, as abnormal phosphate levels may be associated with severe health risks. It is important to monitor serum phosphate levels on a regular basis in these patients; however, such measurements are generally limited to every 0.5-3 months, depending on the severity of CKD.
View Article and Find Full Text PDF